Literature DB >> 16278824

The UMD TP53 database and website: update and revisions.

Dalil Hamroun1, Shunsuke Kato, Chikashi Ishioka, Mireille Claustres, Christophe Béroud, Thierry Soussi.   

Abstract

Mutation of the p53 gene is the most frequent genetic alteration found in human cancer, but it is also the most frequently reported with more than 22,000 mutations published in 2,000 papers. In 1991, we developed a database and software to handle and analyze all this information. The database has been widely used for clinical analysis and molecular epidemiology. We have expanded the scope of the database by integrating structural, phylogenetic and biological information on wild-type (wt) and mutant TP53. Integration of the TP53 mutant activity database provides unique information that will be useful to both clinicians and scientists. All of this information is available from a new website (www.umd.be:2072/) that will generate a detailed informative page for every TP53 mutant in the database. New tools to check TP53 mutations and minimize errors found in the literature are also available. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278824     DOI: 10.1002/humu.20269

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  43 in total

1.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

2.  Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.

Authors:  Samuel A Danziger; Jue Zeng; Ying Wang; Rainer K Brachmann; Richard H Lathrop
Journal:  Bioinformatics       Date:  2007-07-01       Impact factor: 6.937

3.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

4.  Multipattern consensus regions in multiple aligned protein sequences and their segmentation.

Authors:  David K Y Chiu; Yan Wang
Journal:  EURASIP J Bioinform Syst Biol       Date:  2006

5.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

6.  QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants.

Authors:  Shruti Koulgi; Archana Achalere; Neeru Sharma; Uddhavesh Sonavane; Rajendra Joshi
Journal:  J Mol Model       Date:  2013-11-21       Impact factor: 1.810

Review 7.  Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology.

Authors:  Krithika Vaidyanathan; Sean Durning; Lance Wells
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-14       Impact factor: 8.250

8.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

9.  Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.

Authors:  Olga Fedorova; Alexey Petukhov; Alexandra Daks; Oleg Shuvalov; Tatyana Leonova; Elena Vasileva; Nikolai Aksenov; Gerry Melino; Nikolai A Barlev
Journal:  Oncogene       Date:  2018-11-19       Impact factor: 9.867

Review 10.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.